Singapore-founded regenerative medicine company Osteopore Limited (ASX:OSX or the Company) – a global leader in 3D-printed biomimetic and bioresorbable implants – is pleased to confirm that in accordance with the indicative timetable, the Entitlement Offer Prospectus has been despatched today. Tuesday 19 March 2024 to eligible shareholders.The Company is seeking to raise approximately A$3,000,000 (before costs) via a 10- for-1 Renounceable Pro-Rata Entitlement Offer at A$0.029 per share with shareholders to receive one free-attaching option at an exercise price of A$0.0387, which will expire two years from the closing date of the Entitlement Offer, for every 5 new shares subscribed under the Entitlement Offer (Entitlement Offer). Further details of the Entitlement Offer are set out in the prospectus lodged by the Company with ASIC on 13 March 2024 (Prospectus).
